DIGENE ENJOYS GROWTH OF 39% IN RECENT MONTHS FUELED BY RECOGNITION that HPV plays a key role in causing cervical cancer, demand for Digene Corporation’s hc2 High-Risk HPV DNA test is increasing at impressive rates. For fiscal third quarter 2004, Digene reported revenue growth of 39% over the same quarter last year. Its revenues climbed […]
To access this post, you must purchase The Dark Report.